Associate Professor and Honorary Consultant Hepatologist

University of Birmingham

Contact:

Email address: p.j.trivedi@bham.ac.uk
Twitter: @CholestasisDoc

Dr Palak Trivedi

Community Member


Biography

Dr. Trivedi is a Clinician Scientist in the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), based at the University of Birmingham. Dr. Trivedi is a Consultant Hepatologist who has devoted his clinical and research career to studying immune-mediated and chronic cholestatic liver disease, specifically primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).

Palak is chief investigator for the UK-PSC consortium, and was elected chair of the British Association for Study of the Liver Special Interest Group (BASL SIG) for immune-mediated liver disease in 2018.

Palak completed his PhD in Liver Immunology in 2015, securing a competitively awarded Wellcome Trust Clinical Research Fellowship. During this time, his work on risk stratification in PBC was ranked the highest scoring clinical abstract at the EASL International Liver Congress.

Palak went on to receive the Investigator of the Year award in 2017 for work on gut-liver immunity in PSC, was recipient of the Andy Burroughs’ prize for best Hepatology research at the British Association for Study of the Liver (BASL), and won the Elwyn Elias prize for research into PSC and liver transplantation the same year. Palak is currently a mid-career researcher at the University of Birmingham, with 50% protected research time and the remainder dedicated to clinical practice.

Palak currently leads the PBC and PSC clinical research programme, with the overarching themes of work focussing on the role of gut-liver immunity, modelling the natural history of PBC and PSC, generating real-world clinical outcome data, and risk stratification pre- and post-transplantation.

Research Interests:

  • Exercise intervention to attenuate symptoms in cholestasis
  • Epidemiology of primary sclerosing cholangitis
  • Risk stratification in chronic cholestatic liver disease
  • Characterising the natural history of PBC and PSC
  • Gut-liver immunity in the pathogenesis of autoimmune liver disease
  • Clinical trial design in rare disease
  • Immune-therapy induced liver injury
  • Exploring stability and function of regulatory T cells in human livers to develop and deliver immunotherapy for autoimmune hepatitis

Additional HDR Midlands Team Members

Mr Sheikh Momin

Neurosurgery Academic Clinical Fellow
University of Birmingham

Mrs Victoria Cooper

Quality and Governance Lead
University Hospitals Birmingham NHS Foundation Trust

Mr Conor Price

Chief Information Officer
Herefordshire General Practice

Mr Glen Howard

Programme Manager Health Analytics and Informatics
Health Innovation East Midlands